CJC-1295 is categorized as Growth hormone-releasing hormone analog; its regulatory category in this atlas is Investigational or clinic-adjacent peptide.
Human ObservationalPEPTIDE DOSSIER
CJC-1295
CJC-1295 is classified as Growth hormone-releasing hormone analog. This profile separates what is known from source-linked evidence, what remains uncertain, safety considerations, and the US regulatory context.
DAC-GRFModified GRF 1-29
Executive Summary
What is it?
CJC-1295 is a profile in the atlas because people search for it as a peptide, peptide medicine, peptide-like hormone, supplement ingredient, cosmetic peptide, or nearby comparison item. The key question is not just what it is called, but whether a specific product has reliable evidence, clear safety information, and a verified regulatory pathway.
What is it used or studied for?
CJC-1295 is commonly searched in connection with growth hormone pathways, body composition research. Some uses may be approved for specific products, while others may only be studied, speculative, cosmetic, supplement-related, or unsupported.
How it interacts with the body
In simple terms, CJC-1295 is discussed through GHRH receptor agonism with albumin-binding modification in DAC forms. That means the profile focuses on the body signal, receptor, or pathway it is believed or known to affect, while separating proven labeled uses from research-only claims.
What we know
- - CJC-1295 is categorized as Growth hormone-releasing hormone analog.
- - CJC-1295 currently has evidence grade C in this atlas.
- - Regulatory category: Investigational or clinic-adjacent peptide.
What remains uncertain
- - Product-specific legality, quality, and labeling can vary by jurisdiction and supplier.
- - Long-term safety and real-world adverse-event patterns may be incomplete outside approved product contexts.
- - Claims not tied to FDA labeling or human trials should be treated cautiously.
Non-technical takeaway
CJC-1295 should be read through three filters: what the evidence says, what the regulatory status actually means, and what safety uncertainties remain.
People usually search CJC-1295 to understand potential uses, how it works in the body, whether it is approved, and what safety concerns or evidence gaps matter.
Key safety considerations
Safety context for CJC-1295 should be interpreted through product-specific labels or the limits of available research. Non-approved products should not be treated as safe for human use.
Chemical and Scientific Profile
- Peptide type
- Growth hormone-releasing hormone analog
- Sequence
- Unknown
- Formula
- Unknown
- Molecular weight
- Unknown
- CAS number
- Unknown
- PubChem CID
- 91971820
- Targets
- GHRH receptor
- Routes studied
- subcutaneous
Molecular visualization placeholder
Mechanism of Action
Explain like I’m new
CJC-1295 is discussed through the pathway: GHRH receptor agonism with albumin-binding modification in DAC forms. The plain-language interpretation should stay anchored to verified evidence and labeled uses.
Advanced scientific view
Advanced view: GHRH receptor agonism with albumin-binding modification in DAC forms. Receptor/pathway details require claim-level citations before being treated as clinically meaningful.
GHRH receptor agonism with albumin-binding modification in DAC forms
Benefits and Claims
Promising
Preclinical Only
CJC-1295 should be interpreted through source-linked evidence, not marketing claims or protocol claims.
Human ObservationalUnsupported / Safety Claim
CJC-1295 is not presented here with an approved human self-administration protocol; safety and legal status require caution.
UnsupportedEvidence Dashboard
C
Evidence grade
limited human research; not an FDA-approved drug for general marketing
Human data
not yet fully characterized
Animal data
mixed or limited
Citation quality
source search placeholder
Research tracker for CJC-1295
- Population
- Not yet curated from a specific trial.
- Intervention
- CJC-1295
- Comparator
- Not yet curated.
- Outcomes
- Research outcomes require manual source review.
- Limitations
- This study card is a seed-level summary and should be replaced by full PICO extraction during editorial review.
- Funding/conflict
- Funding and conflict notes require editorial extraction from the full source.
Dosing and Administration Guardrails
No FDA-approved human dosing protocol is provided here. This profile does not include self-administration, injection, or reconstitution instructions.
This site does not provide personalized protocols, DIY preparation, injection, reconstitution, or self-administration instructions.
Safety Section
Common side effects
- - not well characterized in this seed
Serious warnings
- - unknown long-term safety or product-specific warning gaps
Contraindications
- - not fully characterized; consult product-specific labeling or clinician
Interactions
- - not fully characterized
Regulatory and Sport Status
Comparisons
Compare evidence, regulatory status, route, and safety context before treating two compounds as similar.
FAQs
Is CJC-1295 FDA-approved?
This seed does not verify CJC-1295 as FDA-approved for general human use. The profile is educational and should not be read as medical advice or a protocol.
What is the main evidence caveat for CJC-1295?
CJC-1295 is categorized as Investigational or clinic-adjacent peptide. Evidence strength depends on whether a claim comes from FDA labeling, human trials, animal studies, in vitro work, or unsupported marketing.
Does this page provide dosing instructions for CJC-1295?
No. For non-approved compounds, this site explicitly avoids self-administration, injection, and dosing protocols.